



## Calithera Biosciences to Report Third Quarter 2015 Financial Results on Monday, November 9, 2015

October 30, 2015

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company's third quarter 2015 financial results will be released on Monday, November 9, 2015. Company management will host a conference call on Monday, November 9, 2015 at 1:15 p.m. Pacific Time/ 4:15 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

The press release and live audio webcast can be accessed via the Investor section of the Company's website at [www.calithera.com](http://www.calithera.com). The conference call can be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and refer to conference ID 62242412. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Calithera's website for 30 days.

### About Calithera Biosciences

Calithera Biosciences is a clinical-stage company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology. Calithera's lead clinical candidate, CB-839, is a first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism, and is currently being tested in patients with solid and hematological cancers. Calithera Biosciences is headquartered in South San Francisco. For more information about Calithera Biosciences, please visit [www.calithera.com](http://www.calithera.com).

CONTACT: Jennifer McNealey  
[ir@Calithera.com](mailto:ir@Calithera.com)  
650-870-1071



Calithera Biosciences, Inc.